Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

I honestly don't think we have to worry much about

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155577
(Total Views: 479)
Posted On: 03/07/2021 4:00:27 PM
Posted By: Cassandra X
I honestly don't think we have to worry much about Cytodyn's future success. People are worrying way too much. Right now, everything is way too FDA-centric. Here is how I see things going.

Cytodyn needs to concentrate on finishing the CD12 Top Line Report as soon as possible. It can then be submitted to the drug authorities in other countries. They do not all work off the same benchmarks as the US FDA and I think they will be more amenable to arguments for Leronlimab's approval or at least EUA.

The Top Line Report can tease out all the nuances in the trial data and make an argument that more clinical considerations should be considered instead of those stupid P values.

The case of every single patient can be gone over with a fine-toothed comb. What treatment did each patient get? Did they get Dexamethasone, an immunosuppressant while they were also getting Leronlimab, an immunity booster? Did severe and critical patients change categories after they were first treated, leaving the Leronlimab arm "underpowered" (less critical patients) because of its success? Was it fair at the end of a trial to separate the benefits to severe patients from those of the critical patients because of an endpoint chosen before anyone knew squat about what caused Covid, almost 12 months ago? Make no mistake - all recipients of Leronlimab benefited to some degree, even the ones too far gone to survive!

The Top Line Report is an argumentative document. It is meant to put the best case forward for the approval of a drug. Cytodyn should do that and give it to the other drug authorities like the MHRA who have already said they are willing to look at out-of-trial data like eIND data and OLE data. It sounds to me like other FDAs are more likely to give approval because of NEWS type standards rather than "P values". More power to them!

Leronlimab works great! Is its treatment benefit to be denied because of trial vagaries? What kind of a world do we live in if it isn't one that is crying out for solutions to the tyranny of this Pandemic?

Sanity will prevail somewhere on this planet if it isn't here in the US with this FDA. Leronlimab and Cytodyn will prevail and thrive. Those who do not enable their forward success will just end up looking stupid.


(8)
(1)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us